Sun Pharmaceutical Industries Limited

NSE SUNPHARMA.NS

Sun Pharmaceutical Industries Limited EBITDA Margin for the year ending March 31, 2024: 28.97%

Sun Pharmaceutical Industries Limited EBITDA Margin is 28.97% for the year ending March 31, 2024, a 3.75% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Sun Pharmaceutical Industries Limited EBITDA Margin for the year ending March 31, 2023 was 27.92%, a 60.16% change year over year.
  • Sun Pharmaceutical Industries Limited EBITDA Margin for the year ending March 31, 2022 was 17.44%, a 15.59% change year over year.
  • Sun Pharmaceutical Industries Limited EBITDA Margin for the year ending March 31, 2021 was 15.08%, a -33.33% change year over year.
  • Sun Pharmaceutical Industries Limited EBITDA Margin for the year ending March 31, 2020 was 22.62%, a 6.67% change year over year.
Key data
Date EBITDA Margin EBIT Margin Depreciation and Amortization EBIT
Market news
Loading...
NSE: SUNPHARMA.NS

Sun Pharmaceutical Industries Limited

CEO Mr. Dilip Shantilal Shanghvi
IPO Date Jan. 1, 1996
Location India
Headquarters Sun House
Employees 43,000
Sector Health Care
Industries
Description

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances; generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; speciality medications, as well as over-the-counter products. The company was founded in 1983 and is based in Mumbai, India.

Similar companies

LUPIN.NS

Lupin Limited

USD 24.89

0.15%

AXISBANK.NS

Axis Bank Limited

USD 12.15

0.37%

CIPLA.NS

Cipla Limited

USD 16.73

0.74%

HCLTECH.NS

HCL Technologies Limited

USD 20.95

-8.71%

DRREDDY.NS

Dr. Reddy's Laboratories Limited

USD 15.45

0.33%

StockViz Staff

January 15, 2025

Any question? Send us an email